Tumor-Infiltrating lymphocyte grade IDs melanoma survival

June 20, 2012
Tumor-Infiltrating lymphocyte grade IDs melanoma survival
Tumor-infiltrating lymphocyte grade is an independent predictor of melanoma-specific survival and sentinel lymph node status in patients with localized primary cutaneous melanoma, according to a study published online June 18 in the Journal of Clinical Oncology.

(HealthDay) -- Tumor-infiltrating lymphocyte (TIL) grade is an independent predictor of melanoma-specific survival and sentinel lymph node (SLN) status in patients with localized primary cutaneous melanoma, according to a study published online June 18 in the Journal of Clinical Oncology.

To investigate whether the density and distribution of TILs independently predicts SLN status and survival, Farhad Azimi, of the Melanoma Institute Australia in Sydney, and colleagues reviewed data from 1,865 patients with a single localized primary cutaneous melanoma ≥0.75 mm in thickness.

The researchers observed an inverse association between TIL grade and tumor thickness, mitotic rate, and Clark level. Sixty-one percent of patients underwent a SLN biopsy and 22.1 percent were positive. SLN positivity decreased with increasing TIL grade, ranging from 27.8 percent for TIL grade 0 to 5.6 percent for TIL grade 3 (P < 0.001). Decreasing age, decreasing TIL grade, ulceration, increasing tumor thickness, satellitosis, and increasing mitoses were significant predictors of SLN positivity. Independent predictors of melanoma-specific survival were tumor thickness, ulceration, satellitosis, mitotic rate, TIL grade, and sex. Survival was 100 percent in those with TIL grade 3.

"Ultimately, a greater understanding of the mechanisms controlling TILs in melanoma may provide avenues for developing important new immunotherapeutic strategies for patients with ," the authors write.

Explore further: Women have clear melanoma survival advantage over men

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Women have clear melanoma survival advantage over men

May 1, 2012
(HealthDay) -- Women with localized melanoma have a consistent advantage over men of approximately 30 percent for survival and progression, according to a study published online April 30 in the Journal of Clinical Oncology.

ASCO: Dabrafenib/Trametinib active in metastatic melanoma

May 17, 2012
(HealthDay) -- For patients with V600 BRAF-mutant solid tumors, treatment with the oral BRAF inhibitor dabrafenib and the oral MEK 1/2 inhibitor trametinib is tolerated and has clinical activity in BRAF inhibitor-naive metastatic ...

Ipilimumab active in advanced melanoma with brain mets

March 27, 2012
(HealthDay) -- For some patients with advanced melanoma and brain metastases, ipilimumab is active, according to the results of a phase 2 study published online March 27 in The Lancet Oncology.

Invasive melanoma may be more likely in children than adults

October 5, 2011
A Johns Hopkins Children's Center study of young people with melanoma, a deadly form of skin cancer, has found that some children have a higher risk of invasive disease than adults.

Sentinel node biopsy safe, effective in head and neck melanomas

August 5, 2011
A common technique for determining whether melanoma has spread can be used safely and effectively even in tumors from the head and neck area, according to a new study from the University of Michigan Comprehensive Cancer Center.

Recommended for you

Lung cancer triggers pulmonary hypertension

November 17, 2017
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart ...

Researchers discover an Achilles heel in a lethal leukemia

November 16, 2017
Researchers have discovered how a linkage between two proteins in acute myeloid leukemia enables cancer cells to resist chemotherapy and showed that disrupting the linkage could render the cells vulnerable to treatment. St. ...

Computer program finds new uses for old drugs

November 16, 2017
Researchers at the Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, ...

Pharmacoscopy improves therapy for relapsed blood cancer in a first clinical trial

November 16, 2017
Researchers at CeMM and the Medical University of Vienna presented a preliminary report in The Lancet Hematology on the clinical impact of an integrated ex vivo approach called pharmacoscopy. The procedures measure single-cell ...

Wider sampling of tumor tissues may guide drug choice, improve outcomes

November 15, 2017
A new study focused on describing genetic variations within a primary tumor, differences between the primary and a metastatic branch of that tumor, and additional diversity found in tumor DNA in the blood stream could help ...

A new strategy for prevention of liver cancer development

November 14, 2017
Primary liver cancer is now the second leading cause of cancer-related death worldwide, and its incidences and mortality are increasing rapidly in the United Stated. In late stages of the malignancy, there are no effective ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.